AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03952858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
Study NCT02030015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Description: The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
Study NCT02030015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
Study NCT00977353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: 20-60 mg/day, oral, for 6 weeks
Study NCT00977353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarcosine
Description: 500-1500 mg/day, oral, for 6 weeks
Study NCT03149432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
Study NCT00522288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Description: Daily wear soft contact lenses disposed of daily or biweekly
Study NCT00522288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle
Description: Spectacles for the treatment of myopia
Study NCT03399422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
Study NCT03399422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: canine retraction
Description: upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
Study NCT00728468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
Study NCT02224768 — intervention group
Intervention type: DRUG
Intervention: Ipilimumab
Study NCT01541462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weaning
Description: Decrease assistance provided by the ventilator
Study NCT00990834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 80 mg PO daily for one to eight months.
Study NCT01258608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapatumumab
Description: Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
Study NCT01258608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
Study NCT01258608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
Study NCT03149432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
Study NCT03149432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
Study NCT01258608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
Study NCT03248102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blowing into the mouthpiece
Description: Blowing into the mouthpiece of diagnostic device
Study NCT01719835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750mg/m2 IV every 21 days
Study NCT03183466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic repair
Study NCT03183466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic debridement
Study NCT00000372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Study NCT00000372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine
Study NCT00000372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Study NCT00000372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clozapine
Study NCT00000372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05101499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AKIN osteotomy with screw fixation
Description: A simple skin speck is made on the medial aspect of the hallux, in the metaphyseal area, using a 3 mm beaver blade. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.~Fixation with a screw will be effected by another skin speckle allowing access to the infero-medial area of the phalangeal base. A pre-hole can be made with the same bur to facilitate the introduction of the guide wire for osteosynthesis, which is not specific.
Study NCT05101499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AKIN osteotomy without screw fixation
Description: This is the same procedure as the procedure under study, without the fixation by a target: a simple skin speck is performed on the medial face of the hallux, in the metaphyseal area using a beaver blade. of 3 mm. The tissue is lifted from the bone using an elevator medially and dorsally on the phalanx. A Shannon 2x12 mm burr is then positioned transversely by making the osteotomy which must preserve a lateral hinge, a guarantee of stability in the event of non-fixation.
Study NCT04473079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacidofil
Description: Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
Study NCT04473079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigational product intake daily for 6 weeks. Co-administration of H. pylori treatment with investigational product the first two weeks only.
Study NCT00593996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ergocalciferol (vitamin D2)
Description: 50,000 IU 3 times weekly for 4 weeks
Study NCT03605615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vocalization
Description: The vocalization will be taught in voice form exhaled / sung in grave tones with the vowels, A, O and U.
Study NCT03824210 — intervention group
Intervention type: OTHER
Intervention: App
Description: Mobile phone app
Study NCT03848585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pilloxa Pillbox
Description: A Pilloxa Pillbox is used for the prescribed immunosuppressants.
Study NCT03848585 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non active Pilloxa Pillbox
Description: A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
Study NCT00062309 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT01719835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 IV Days 1, 8, 15 every 28 days
Study NCT01719835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50mg/m2 IV every 21 days
Study NCT01719835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m2 (max 2mg) IV every 21 days
Study NCT01719835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 100mg PO Days 1-5 every 21 days
Study NCT01719835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 1000mg oral or IV Days 1-5 every 28 days
Study NCT01719835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m2 IV Day 15 every 28 days
Study NCT01297231 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).~During Tamoxifen Treatment:~* Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.~* Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.~* Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated.
Study NCT02070055 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT04354467 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine neutrophil gelatinase -associated lipocalin
Description: urine biomarker is measured and batched procesessed
Study NCT03853668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
Study NCT03853668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
Study NCT01140217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone Acetate
Description: Norethindrone Acetate Transdermal Delivery System
Study NCT02319811 — intervention group
Intervention type: PROCEDURE
Intervention: Cryopreserved meniscus transplants
Description: Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
Study NCT04710810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: umbilical cord blood mononuclear stem cells
Description: UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.
Study NCT02538731 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: dilation-assisted stone extraction
Study NCT02538731 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spyglass Guided Laser Lithotrips
Study NCT00745745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device Implantation
Description: ICD lead implantation
Study NCT00745745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Implantation
Description: ICD lead implantation
Study NCT01235390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: The consumption of assigned walnuts once a day during 4 weeks
Study NCT01744522 — intervention group
Intervention type: PROCEDURE
Intervention: Leech therapy
Description: Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
Study NCT03149432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
Study NCT03149432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local care
Description: local care for directed healing of the stump.
Study NCT03149432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local care
Description: local care for directed healing of the stump.
Study NCT00729508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Cat-PAD dose 2X 4 administrations 2 weeks apart
Study NCT01093118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMI-358
Description: Micro implant monthly x 3
Study NCT01093118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMI-467
Description: Micro implant monthly x 3
Study NCT04098939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diaphragm evaluation
Description: Ultrasound and radiographic evaluation of diaphragm function
Study NCT05924542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kelaa Mental Resilience App
Description: Users can track their stress, wellbeing, and resilience via short in-app questionnaires. The app uses inbuilt sensors in smartphones to measure sleep quality and quantity. Personalized feedback on questionnaire scores and on sleep data are given. Users access structured science-based content on factors contributing to reduced stress and improved well-being. Kelaa provides the user with evidence-based interventions grounded in current research, e.g., from sleep science and psychology. Users can choose from a variety of topics, based on their results from the tracking module and personal interest, and then journey through the self-selected goals. Each goal includes six to seven daily sessions, aiming to increase personal resources by providing information, exercises, and reflection. During each daily session, relevant research and expected benefits are outlined, before users are instructed, e.g., in specific stress management and resilience techniques, to encourage behavior change.
Study NCT01580072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-monitoring for patients with severe COPD
Description: Intervention Group entering vital parameters via Web Portal or automatic call center.
Study NCT01580072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-monitoring for patients with severe COPD
Description: Nurses are entering vital parameters of the patient with mobile devices.
Study NCT01106833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus + calcineurin inhibitor + prednisone
Description: The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day.
Study NCT01106833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus + prednisone
Description: The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day.
Study NCT02698124 — intervention group
Intervention type: DRUG
Intervention: Decitabine
Study NCT04130516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
Description: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
Study NCT04130516 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pembrolizumab - anti-PD-1 antibody
Description: pembrolizumab- anti-PD-1 antibody
Study NCT02598492 — intervention group
Intervention type: OTHER
Intervention: arterial blood gas
Description: Just record clinical lab data
Study NCT00587327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barusiban
Description: Solution for IV treatment. Bolus and infusion for 4 hours
Study NCT00587327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Solution for IV administration. Bolus and infusion for 4 hours
Study NCT00587327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for IV administration. Bolus and infusion for 4 hours.
Study NCT01911403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Closure procedure by Manual compression
Study NCT01911403 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-Seal
Description: Closure procedure by angio-Seal
Study NCT00062309 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04638985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV+DTaP+MMR
Description: sIPV+DTaP+MMR at the age of 18 month old
Study NCT04638985 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sIPV
Description: sIPV at the age of 18 month old
Study NCT04638985 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP
Description: DTaP at the age of 18 month old
Study NCT03722927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
Study NCT03722927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
Study NCT02200718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroVax
Description: NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
Study NCT02200718 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IFA Incomplete Freund's Adjuvant
Description: IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
Study NCT04638985 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR
Description: MMR at the age of 18 month old
Study NCT00927459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-040201
Description: Single dose IV infusion
Study NCT04376138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCI intervention
Description: 30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
Study NCT04376138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: 30 minutes intervention that occurs 3 times per week, with a goal of 12 sessions total.
Study NCT02985866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Use of CTR at home for 3 months
Study NCT02985866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensor Augmented Therapy
Description: Use of personal pump with study CGM \& glucometer at home for 3 months
Study NCT00201084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uncertainty reduction
Description: At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling